- Home
- FFC vs CVAC Comparison
FFC vs CVAC Comparison
Compare FFC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- CVAC
- Stock Information
- Founded
- FFC 1983
- CVAC 2000
- Country
- FFC United States
- CVAC Germany
- Employees
- FFC N/A
- CVAC N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- CVAC Health Care
- Exchange
- FFC Nasdaq
- CVAC Nasdaq
- Market Cap
- FFC 741.9M
- CVAC 764.4M
- IPO Year
- FFC N/A
- CVAC 2020
- Fundamental
- Price
- FFC $16.24
- CVAC $5.40
- Analyst Decision
- FFC
- CVAC Hold
- Analyst Count
- FFC 0
- CVAC 3
- Target Price
- FFC N/A
- CVAC $6.83
- AVG Volume (30 Days)
- FFC 164.1K
- CVAC 2.1M
- Earning Date
- FFC 01-01-0001
- CVAC 08-14-2025
- Dividend Yield
- FFC 6.79%
- CVAC N/A
- EPS Growth
- FFC N/A
- CVAC N/A
- EPS
- FFC N/A
- CVAC 0.87
- Revenue
- FFC N/A
- CVAC $566,039,775.00
- Revenue This Year
- FFC N/A
- CVAC N/A
- Revenue Next Year
- FFC N/A
- CVAC $24.04
- P/E Ratio
- FFC N/A
- CVAC $6.24
- Revenue Growth
- FFC N/A
- CVAC 787.60
- 52 Week Low
- FFC $11.90
- CVAC $2.37
- 52 Week High
- FFC $14.96
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- FFC 63.27
- CVAC 65.68
- Support Level
- FFC $15.84
- CVAC $5.30
- Resistance Level
- FFC $16.14
- CVAC $5.58
- Average True Range (ATR)
- FFC 0.12
- CVAC 0.15
- MACD
- FFC 0.00
- CVAC 0.00
- Stochastic Oscillator
- FFC 86.58
- CVAC 80.66
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.